Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 43Other hematologic neoplasm 17Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Sarcoma, Myeloid 1Leukemia, Myeloid 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Blast Crisis 1

Interventions

Cyclophosphamide 67fludarabine phosphate 62Peripheral Blood Stem Cell Transplantation 51Mycophenolic Acid 44Cyclosporine 39Whole-Body Irradiation 38Antilymphocyte Serum 37Tacrolimus 36Busulfan 35Filgrastim 32Radiotherapy 29Methotrexate 23Methylprednisolone 22Melphalan 22Cord Blood Stem Cell Transplantation 21fludarabine 13Etoposide 12Psychiatric Rehabilitation 10Flow Cytometry 10Therapeutics 9Sirolimus 9Granulocyte Colony-Stimulating Factor 8Cytarabine 8Thiotepa 7Alemtuzumab 7Polymerase Chain Reaction 6thymoglobulin 5sargramostim 5Prednisone 5Cyclosporins 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Burkitt Lymphoma × blinatumomab × Myeloid × Clear all
NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Ascentage Pharma Group Inc.

Phase 1 Recruiting
242 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Dana-Farber Cancer Institute

Phase 1 Recruiting
40 enrolled
LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡